Literature DB >> 7736522

Comparison of the cellular internalization of antibodies used either as immunotoxins or in ADEPT.

D C Blakey1, P E Pinder, A F Wright.   

Abstract

The internalization into tumor cells of two antibodies (C242 and 454A12), which make potent immunotoxins when linked to ricin A-chain, and an antibody (A5B7), which does not make a potent immunotoxin but has proven useful in ADEPT, was evaluated. The 454A12 antibody was rapidly taken into the cells, 50% of the antibody being internalized after 2 h. The C242 antibody was internalized more slowly, approx 50% being taken up by the cells in 24 h. With A5B7, less than 10% of the antibody was internalized after 24 h. Internalization of the C242 antibody was accompanied by the appearance of antibody degradation products in the cell medium after 2 h, and this degradation could be inhibited by addition of a metabolic inhibitor that prevented cell internalization. In contrast, minimal degradation of the A5B7 antibody could be detected up to 24 h after binding to the cells. In conclusion, both 454A12 and C242 antibodies, which make potent immunotoxins, were internalized into tumor cells. The A5B7 antibody, which does not make a potent immunotoxin, was not internalized, and this property may be one reason why A5B7 has proved useful for delivery of enzymes in ADEPT.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7736522     DOI: 10.1007/bf02789228

Source DB:  PubMed          Journal:  Cell Biophys        ISSN: 0163-4992


  9 in total

1.  Strategies in antibody therapy of cancer.

Authors:  E J Wawrzynczak; A J Davies
Journal:  Clin Exp Immunol       Date:  1990-11       Impact factor: 4.330

2.  Mouse monoclonal antibodies for experimental immunotherapy promotes killing of tumor cells.

Authors:  L N Larson; C Johansson; L Lindholm; J Holmgren
Journal:  Int J Cancer       Date:  1988-12-15       Impact factor: 7.396

3.  Endocytosis and degradation of murine anti-human CD3 monoclonal antibodies by normal and malignant T-lymphocytes.

Authors:  O W Press; J A Hansen; A Farr; P J Martin
Journal:  Cancer Res       Date:  1988-04-15       Impact factor: 12.701

4.  Kinetics of cytotoxicity induced by immunotoxins. Enhancement by lysosomotropic amines and carboxylic ionophores.

Authors:  P Casellas; B J Bourrie; P Gros; F K Jansen
Journal:  J Biol Chem       Date:  1984-08-10       Impact factor: 5.157

5.  In vitro and in vivo enhancement of ricin-A chain immunotoxin activity by novel indolizine calcium channel blockers: delayed intracellular degradation linked to lipidosis induction.

Authors:  J P Jaffrézou; T Levade; O Thurneyssen; M Chiron; C Bordier; M Attal; P Chatelain; G Laurent
Journal:  Cancer Res       Date:  1992-03-01       Impact factor: 12.701

6.  Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer.

Authors:  D J FitzGerald; M J Bjorn; R J Ferris; J L Winkelhake; A E Frankel; T C Hamilton; R F Ozols; M C Willingham; I Pastan
Journal:  Cancer Res       Date:  1987-03-01       Impact factor: 12.701

7.  Antibody directed enzyme prodrug therapy (ADEPT): clinical report.

Authors:  K D Bagshawe; S K Sharma; C J Springer; P Antoniw; J A Boden; G T Rogers; P J Burke; R G Melton; R F Sherwood
Journal:  Dis Markers       Date:  1991 May-Aug       Impact factor: 3.434

8.  Antibody directed enzymes revive anti-cancer prodrugs concept.

Authors:  K D Bagshawe
Journal:  Br J Cancer       Date:  1987-11       Impact factor: 7.640

9.  Antitumor activity of the single-chain immunotoxin BR96 sFv-PE40 against established breast and lung tumor xenografts.

Authors:  P N Friedman; D F Chace; P A Trail; C B Siegall
Journal:  J Immunol       Date:  1993-04-01       Impact factor: 5.426

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.